Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial
Autor: | Alberto Benito-Boillos, José Alfredo Martínez, Maria Angeles Zulet, Itziar Abete, Mariana Elorz, Juan Isidro Uriz-Otano, Bertha Araceli Marin-Alejandre, Jorge Quiroga, María Pilar Huarte-Muniesa, Jose Ignacio Monreal, Ana Martinez-Echeverria, Josep A. Tur, Irene Cantero, José Ignacio Herrero, Nuria Perez-Diaz-Del-Campo |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Mediterranean diet Overweight Gastroenterology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Weight loss Non-alcoholic Fatty Liver Disease Internal medicine Nonalcoholic fatty liver disease Weight Loss medicine Humans Obesity Hepatology Adiponectin business.industry Fatty liver Body Weight medicine.disease Diet Liver 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology medicine.symptom business |
Zdroj: | Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 41(7) |
ISSN: | 1478-3231 |
Popis: | Background and objectives Nonalcoholic fatty liver disease (NAFLD) management is focused on lifestyle modifications, but long-term maintenance is a challenge for many individuals. This study aimed to evaluate the long-term effects of two personalized energy-restricted dietary strategies on weight loss, metabolic and hepatic outcomes in overweight/obese subjects with NAFLD. Methods Ninety-eight subjects from the Fatty Liver in Obesity (FLiO) study (NCT03183193) were randomly assigned to the American Heart Association (AHA) or the FLiO dietary group in a 2-year controlled trial. Anthropometry, body composition (DXA), biochemical parameters and hepatic status (ultrasonography, Magnetic Resonance Imaging, and elastography) were assessed at baseline, 6, 12 and 24 months. Results Both the AHA and FLiO diets significantly reduced body weight at 6 (-9.7% vs -10.1%), 12 (-6.7% vs -9.6%), and 24 months (-4.8% vs -7.6%) with significant improvements in body composition, biochemical and liver determinations throughout the intervention. At the end of the follow-up, the FLiO group showed a greater decrease in ALT, liver stiffness and Fatty Liver Index, among others, compared to AHA group, although these differences were attenuated when the analyses were adjusted by weight loss percentage. The FLiO group also showed a greater increase in adiponectin compared to AHA group. Conclusions The AHA and FLiO diets were able to improve body weight and body composition, as well as metabolic and hepatic status of participants with overweight/obesity and NAFLD within a 2-year follow-up. These findings show that both strategies are suitable alternatives for NAFLD management. However, the FLiO strategy may provide more persistent benefits in metabolic and hepatic parameters. |
Databáze: | OpenAIRE |
Externí odkaz: |